Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study - Wikidata - wikimedia - TriplyDB

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study

http://www.wikidata.org/entity/Q33695128

about

Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.B Cell-Based Treatments in SLE: Past Experience and Current Directions.Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner.Semaphorin3A: A Potential Therapeutic Tool for Lupus Nephritis.

P2860

Q47552016-0C81C0AE-C0A4-4457-A27F-BBE6723FE1C1 Q47660691-F510C294-8410-4508-97AA-4CC605046EA2 Q55282858-7189957B-8672-45B4-8A52-7BB251FBABB3 Q55399992-E1313406-F175-4B31-BEFA-136FECD81B68

P2860

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study

http://www.wikidata.org/entity/Q33695128

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Belimumab use, clinical outcom ...... from the OBSErve Canada Study

@ast

Belimumab use, clinical outcom ...... from the OBSErve Canada Study

@en

type

label

Belimumab use, clinical outcom ...... from the OBSErve Canada Study

@ast

Belimumab use, clinical outcom ...... from the OBSErve Canada Study

@en

prefLabel

Belimumab use, clinical outcom ...... from the OBSErve Canada Study

@ast

Belimumab use, clinical outcom ...... from the OBSErve Canada Study

@en

P1433

Q33695128-2A398952-D3A0-4647-AFB6-AD542582F616

P1476

Q33695128-97D6C5CB-C2EA-4EB3-90EB-042E2EA427CC

P2093

Q33695128-409F4438-B165-4BA6-AEEB-83FD40C6C688

Q33695128-43287D09-D687-48E0-BA06-F0DA860DF60C

Q33695128-4A28AF33-0689-453E-B7D4-387DAFB626BC

Q33695128-7CEF53E4-1674-4CCC-895D-C25BF6168462

Q33695128-AE2908FF-CF32-43A0-BE50-334826A00C4B

Q33695128-B220974E-7010-4307-B359-5CA598C15D4D

Q33695128-DE2C963C-C73F-4E46-BA7C-554C6B3D2EC9

P2860

Q33695128-1CA6F4C6-3FF5-4E95-B454-743112E87CB3

Q33695128-2527B394-1EFF-448F-8E06-66A9F59AD9D5

Q33695128-396D6CFD-7FB6-4AB1-96A5-C3F441859D00

Q33695128-5DEFA2E6-6BF5-48C6-993F-39563A93E56D

Q33695128-68FD7C09-A3EF-4B1F-B018-FC66BAAA7525

Q33695128-848A2F89-893C-4348-8D94-63E564D32184

Q33695128-8D3609BF-DF02-4A09-BA2D-C516953583FC

Q33695128-A87F6B7C-5EDB-4601-B927-1E6D38696B45

Q33695128-B165D98C-BE55-466A-869B-9E89F23D7462

Q33695128-B3B7A6A3-86FB-44A4-B45D-93B619F27AC8

P2888

Q33695128-3F975BB4-DFA3-4405-9CAE-42F7846968B8

P304

Q33695128-BAC9EA93-005E-46BD-AC1E-02295F316DB0

P31

Q33695128-4CE95221-6963-4CAB-850C-A6587DD82A8B

P356

Q33695128-C71AAB7D-2A7C-42D8-9519-C39B0650498A

P433

Q33695128-D0E06AD2-76DB-45A2-BB24-C8287A56A57D

P478

Q33695128-1F45D8E0-9334-4513-8E70-98A6D0994106

P50

Q33695128-1DF7E562-5070-4FB6-B169-F2A476D9872B

P577

Q33695128-E0E73D5F-67D7-40DB-BD4B-475D5C45CF29

P6179

Q33695128-5711A9E0-9E5A-431B-9B46-2A9D31B79C1C

P698

Q33695128-8E0B16C6-AB1F-47F7-9F4D-2035275555A8

P921

Q33695128-E5BC1CF6-5410-463F-9D01-A2DE194C7EF9

P932

Q33695128-91F7E57C-2D7F-49A5-8029-8F3C224CE2B8

P356

S00296-017-3682-9

P1433

Rheumatology International

P1476

Belimumab use, clinical outcom ...... from the OBSErve Canada Study

@en

P2093

Amyn Sayani

http://www.w3.org/2001/XMLSchema#string

Andrew Chow

http://www.w3.org/2001/XMLSchema#string

Christian A Pineau

http://www.w3.org/2001/XMLSchema#string

George A Ecker

http://www.w3.org/2001/XMLSchema#string

Isabelle Fortin

http://www.w3.org/2001/XMLSchema#string

Mark Matsos

http://www.w3.org/2001/XMLSchema#string

Sandra Iczkovitz

http://www.w3.org/2001/XMLSchema#string

P2860

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Management of lupus erythematosus: recent insights.

A population-based assessment of systemic lupus erythematosus incidence and prevalence--results and implications of using administrative data for epidemiological studies.

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

Treatment of lupus with corticosteroids.

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA.

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

Mortality and causes of death in systemic lupus erythematosus.

P2888

s00296-017-3682-9

P304

865-873

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00296-017-3682-9

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084020652

http://www.w3.org/2001/XMLSchema#string

P698

28280970

http://www.w3.org/2001/XMLSchema#string

P921

P932

5434147

http://www.w3.org/2001/XMLSchema#string